These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 25037982

  • 1. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW.
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E, Canessa PA, Ferro P, Franceschini MC, Fontana V, Dessanti P, Pinelli V, Morabito A, Fedeli F, Pistillo MP, Roncella S.
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
    Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M, Che G.
    Oncotarget; 2017 Jul 11; 8(28):46425-46435. PubMed ID: 28507279
    [Abstract] [Full Text] [Related]

  • 4. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.
    Creaney J, Dick IM, Robinson BW.
    Curr Opin Pulm Med; 2015 Jul 11; 21(4):352-6. PubMed ID: 26016578
    [Abstract] [Full Text] [Related]

  • 5. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.
    Lung Cancer; 2013 Dec 11; 82(3):491-8. PubMed ID: 24161718
    [Abstract] [Full Text] [Related]

  • 6. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E.
    Carcinogenesis; 2019 Nov 25; 40(11):1320-1331. PubMed ID: 31169881
    [Abstract] [Full Text] [Related]

  • 7. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
    Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C.
    N Engl J Med; 2012 Oct 11; 367(15):1417-27. PubMed ID: 23050525
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
    Tsim S, Kelly C, Alexander L, McCormick C, Thomson F, Woodward R, Foster JE, Stobo DB, Paul J, Maskell NA, Chalmers A, Blyth KG.
    BMJ Open; 2016 Nov 24; 6(11):e013324. PubMed ID: 27884852
    [Abstract] [Full Text] [Related]

  • 9. Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
    Sato T, Suzuki Y, Mori T, Maeda M, Abe M, Hino O, Takahashi K.
    Cancer Med; 2014 Oct 24; 3(5):1377-84. PubMed ID: 25045139
    [Abstract] [Full Text] [Related]

  • 10. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, Tagawa M, Metintas M.
    BMC Cancer; 2017 Mar 23; 17(1):212. PubMed ID: 28335760
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.
    Cancer Invest; 2013 Jan 23; 31(1):43-50. PubMed ID: 23249166
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Katz SI, Roshkovan L, Berger I, Friedberg JS, Alley EW, Simone CB, Haas AR, Cengel KA, Sterman DH, Albelda SM.
    Lung Cancer; 2021 Apr 23; 154():5-12. PubMed ID: 33561782
    [Abstract] [Full Text] [Related]

  • 16. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    Tsim S, Alexander L, Kelly C, Shaw A, Hinsley S, Clark S, Evison M, Holme J, Cameron EJ, Sharma D, Wright A, Grundy S, Grieve D, Ionescu A, Breen DP, Paramasivam E, Psallidas I, Mukherjee D, Chetty M, Cox G, Hart-Thomas A, Naseer R, Edwards J, Daneshvar C, Panchal R, Munavvar M, Ostroff R, Alexander L, Hall H, Neilson M, Miller C, McCormick C, Thomson F, Chalmers AJ, Maskell NA, Blyth KG.
    J Thorac Oncol; 2021 Oct 23; 16(10):1705-1717. PubMed ID: 34116230
    [Abstract] [Full Text] [Related]

  • 17. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.
    Ann Thorac Surg; 2008 Jan 23; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [Abstract] [Full Text] [Related]

  • 18. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, Goparaju CM, Prokrym K, Canino C, Pass HI, Carbone M, Yang H.
    Clin Cancer Res; 2016 Jun 15; 22(12):3087-96. PubMed ID: 26733616
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
    Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW.
    Dis Markers; 2014 Jun 15; 2014():413946. PubMed ID: 25505814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.